Please use this identifier to cite or link to this item: https://hdl.handle.net/1/157
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPasricha, Sant-Raynen
dc.contributor.authorFlecknoe-Brown, Stephenen
dc.contributor.authorAllen, Katrinaen
dc.contributor.authorGibson, Peter Ren
dc.contributor.authorMcMahon, L.P.en
dc.contributor.authorOlynyk, Johnen
dc.contributor.authorRoger, Simon Den
dc.contributor.authorSavoia, Helenen
dc.contributor.authorTampi, Ramdasen
dc.contributor.authorThompson, Amanda Ren
dc.contributor.authorWood, Ericaen
dc.contributor.authorRobinson, Kathrynen
dc.date.accessioned2015-03-31T00:30:33Zen
dc.date.available2015-03-31T00:30:33Zen
dc.date.issued2010-11en
dc.identifier.citationVolume 193, Issue 9, pp. 525-532en
dc.identifier.issn0025-729Xen
dc.identifier.urihttps://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/157en
dc.description.abstractIron deficiency anaemia (IDA) remains prevalent in Australia and worldwide, especially among high-risk groups. IDA may be effectively diagnosed in most cases by full blood examination and serum ferritin level. Serum iron levels should not be used to diagnose iron deficiency. Although iron deficiency may be due to physiological demands in growing children, adolescents and pregnant women, the underlying cause(s) should be sought. Patients without a clear physiological explanation for iron deficiency (especially men and postmenopausal women) should be evaluated by gastroscopy/colonoscopy to exclude a source of gastrointestinal bleeding, particularly a malignant lesion. Patients with IDA should be assessed for coeliac disease. Oral iron therapy, in appropriate doses and for a sufficient duration, is an effective first-line strategy for most patients. In selected patients for whom intravenous (IV) iron therapy is indicated, current formulations can be safely administered in outpatient treatment centres and are relatively inexpensive. Red cell transfusion is inappropriate therapy for IDA unless an immediate increase in oxygen delivery is required, such as when the patient is experiencing end-organ compromise (eg, angina pectoris or cardiac failure), or IDA is complicated by serious, acute ongoing bleeding. Consensus methods for administration of available IV iron products are needed to improve the utilisation of these formulations in Australia and reduce inappropriate transfusion. New-generation IV products, supported by high-quality evidence of safety and efficacy, may facilitate rapid administration of higher doses of iron, and may make it easier to integrate IV iron replacement into routine care.en
dc.subjectHaematologyen
dc.subjectHematologyen
dc.subjectAnaemiaen
dc.subjectAnemiaen
dc.titleDiagnosis and management of iron deficiency Anaemia: A clinical updateen
dc.typeJournal Articleen
dc.description.pubmedurihttp://www.ncbi.nlm.nih.gov/pubmed/25415807en
dc.identifier.journaltitleMedical Journal of Australiaen
dc.type.studyortrialReviews/Systematic Reviewsen
dc.originaltypeTexten
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
Appears in Collections:Renal Medicine
Show simple item record

Page view(s)

106
checked on Nov 26, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.